|
Sunday, 08/04/2013
|
LC-MRM-MS Data Analysis Strategy
Ming Li, VICC-Cancer Biostatistics Division
2:05 PM
|
A Simulation Study to Compare Modeling Methods for Analyzing Biomarker Data Subject to a Limit of Detection (LOD)
Charles Rose, CDC; Ryan E. Wiegand, Centers for Disease Control and Prevention
2:05 PM
|
Efficient Pooling Methods for Skewed Biomarker Data Subject to Regression Analysis
Emily Mitchell, Emory University; Robert H. Lyles, Emory University; Michelle Danaher, Eunice Kennedy Shriver National Institute of Child Health and Development; Neil J. Perkins, Eunice Kennedy Shriver National Institute of Child Health and Development; Enrique F. Schisterman, Eunice Kennedy Shriver National Institute of Child Health and Development
2:50 PM
|
The Effect of Precision at the Decision Point on Diagnostics Accuracy of a Biomarker Assay
Jeng Mah, Beckman Coulter, Inc.
3:05 PM
|
Comparison of Dependent Deattenuated Correlation Coefficients
Bernard Rosner, Harvard Medical School; Wei Wang, Brigham & Women's Hospital; Eileen Hibert, Brigham & Women's Hospital
3:05 PM
|
Quantitative Imaging Biomarker and Noise Characteristics in CT
Hyun (Grace) Kim, UCLA; David Gjertson, UCLA School of Public Health; Matthew Brown, UCLA Computer Vision and Imaging Biomarker; Jonathan Goldin, UCLA Radiology
3:25 PM
|
Role of Exploratory Biomarker and Exposure-Response Analyses in Evidence-Based Designs
Li Chen, Amgen Inc.; Hongjie Deng, Amgen Inc.; Erik Rasmussen, Amgen Inc.; Rui Tang, Amgen; Mike Hale, Amgen
3:25 PM
|
Recent Development in Biomarker and Subgroup Identification for Tailored Therapeutics
Russell Wolfinger, SAS Institute Inc; Richard C. Zink, JMP Life Sciences, SAS Institute, Inc.
4:05 PM
|
Study Design and Statistical Methodology in Biomarker Evaluation
Qian Li, NIH, NCCAM
4:20 PM
|
A Resampling-based Ensemble Tree Method to Identify Patient Subgroups with Enhanced Treatment Effect
Chakib Battioui, Eli Lilly & Company; Lei Shen, Eli Lilly & Company; Stephen J. Ruberg, Eli Lilly & Company
4:25 PM
|
Bi-Level Groupwise Multiple Features Selection Method for Identifying Novel Biomarkers in Pharmacogenetic Studies
Ting-Huei Chen, UNC at Chapel Hill; Wei Sun, UNC Chapel Hill
4:35 PM
|
Testing Pathway-Dose Interaction in Clinical Studies
Jia Kang, Merck
4:50 PM
|
Statistical Methods and General Principles of Exploratory Biomarker Analysis: Pathway to Personalized Medicine
Rui Tang, Amgen; Mike Hale, Amgen; Jing Huang, Amgen; Li Chen, Amgen Inc.
5:05 PM
|
Determining Multimodal Biomarkers for Neurodegenerative Diseases
DuBois Bowman, Emory University; Wenqiong Xue, Emory University
5:05 PM
|
Estimating Biological Age Using Ensemble-Based Prediction Models
Wendy Shih; Steve Horvath, University of California, Los Angeles
5:20 PM
|
|
Monday, 08/05/2013
|
Joint Modeling of Latent Group-Based Trajectory Models with Subdistributions
Nilesh Shah, University of Pittsburgh; Chung-Chou H. Chang, University of Pittsburgh; John A. Kellum, University of Pittsburgh
|
Sample Size Calculations for Treatment and Biomarker Interactions
Scarlett Kazimer
|
Asthma and Clinical Challenges in Clinical Trials
Jonathan Goldin, UCLA Radiology
8:35 AM
|
Addressing Within-Subject Genomic Heterogeneity
Matthew Nicholson McCall, University of Rochester Medical Center; Anthony Almudevar, University of Rochester Medical Center
8:40 AM
|
Biomarker Cutoff Identification in Clinical Trials with Biomarker-Driven Subgroups
Lin Wang, Sanofi, US; Lynn Wei, Sanofi, US
8:50 AM
|
Patient-Reported Outcome and Biomarkers in Asthma
Wen-Hung Chen, United BioSource Corporation; Gary Globe, Amgen Inc.; Ingela Wiklund, United BioSource Corporation; Seppi Lin, Amgen Inc.; Michael Schatz, Kaiser Permanente Medical Center; Maria Mattera, United BioSource Corporation; Yun Chon, Amgen Inc.
8:55 AM
|
Nonlinear Mixed Effects Models to Study Determinants of Local Airway Inflammation Using Multiple Flow Exhaled Nitric Oxide Data
Sandrah Eckel, University of Southern California; Kiros Berhane, University of Southern California; Meng Liu, University of Southern California; Linn S William, University of Southern California; Muhammad T. Salam, University of Southern California; Edward B. Rappaport, University of Southern California; Frank D. Gilliland, University of Southern California
8:55 AM
|
Nonparametric Testing Methods for Treatment-Biomarker Interaction Based on Local Partial-Likelihood
Yicong Liu, Queen's University; Wenyu Jiang, Queen's University; Bingshu E. Chen, NCIC Clinical Trials Group and Department of Community Health and Epidemiology, Queen's U
9:05 AM
|
Overview of Study Designs for Personalized Medicine
Lei Zhu, Boston University; Sandeep Menon, Pfizer Inc.; Siyan Xu, Boston University
9:05 AM
|
Personalized Medicine in Oncology: A Statistical Perspective
Cheng Rong, Amgen
9:20 AM
|
Trial Duration and Sample Size Trade-Off When There Are Subgroups with Different Expected Treatment Effects
Kyle D. Rudser, University of Minnesota; Edward Bendert, Statistics Collaborative; Joseph S. Koopmeiners, University of Minnesota
9:35 AM
|
Mixture Representation of Efficacy Measures in Biomarker Studies
Jason Hsu, Ohio State University; Szu-Yu Tang, Ventana Medical Systems, Inc.
9:50 AM
|
Evaluating Marker-Guided Treatment Selection Strategies
Junlong Li, Harvard University; Roland Matsouaka, Harvard University; Tianxi Cai, Harvard University
10:05 AM
|
Quantitative Considerations for Enrichment Clinical Trial Implementation: Marker Prevalence, Effect Size, Diagnostic Assay Performance, Sample Size, and Beyond
Ray Liu, Columbia
10:55 AM
|
Regression When the Predictor may be Censored
David Oakes, Univ of Rochester Medical Center
11:15 AM
|
Decisionmaking for Enrichment Clinical Trial Implementation: Effect of Trial Strategies on Operations and Revenues
Feng Gao, Millennium; Hongliang Shi, Millennium; Yanyan Zhu, Millennium
11:15 AM
|
Regularized Canonical Correlation and Application to High-Dimensional Biomarker Data with Survival Endpoint
Li Liu, Sanofi
11:20 AM
|
Integrating Multi-Layered Data for Biomarker Discovery
Jean Yee Hwa Yang, University of Sydney; Kaushala Jayawardana, University of Sydney; Samuel Mueller, University of Sydney
11:25 AM
|
Biomarker Thresholding to Identify Subgroup of Patients with Treatment Benefit
Yi Liu, Millennium : The Takeda Oncology Company; Jason Hsu, Ohio State University
11:35 AM
|
Statistical Inference for Nonlinear Functional Models with Application to Copy Number Variation and Multiple Myeloma Data
Adrian Coles, North Carolina State University; Arnab Maity, North Carolina State University; Veera Baladandayuthapani, The University of Texas MD Anderson Cancer Center; Ganiraju Manyam, The University of Texas M.D. Anderson Cancer Center
2:20 PM
|
|
Tuesday, 08/06/2013
|
How Biomarker Collection Date Influence Death Rates
Ngoc Ho
|
Exploratory Subgroup Analysis: Subgroup Identification Approaches in Clinical Trials
Ilya Lipkovich; Alexei Dmitrienko, Quintiles
8:35 AM
|
Strategy in Dichotomizing a Continuous Biomarker for Survival Data Analysis
Dung-Tsa Chen, Moffitt Cancer Center; Ying-Lin Hsu, National Chung Hsing University, Taiwan; Po-Yu Huang, National Chung Hsing University, Taiwan
8:50 AM
|
Survival-Related Prognostic Threshold on Quantitative Biomarkers
Xinhua Liu, Columbia University; Zhezhen Jin, Columbia University
8:55 AM
|
Analysis of Left-Censored Multiplex Immunoassay Data: A Unified Approach
Elizabeth Hill, Medical University of South Carolina; Elizabeth Slate, Florida State University
10:10 AM
|
Estimation from a Two-Stage Biomarker Study Allowing Early Termination for Futility
Shanshan Zhao, Fred Hutchinson Cancer Research Center; Ziding Feng, Fred Hutchinson Cancer Research Center
11:20 AM
|
Using Incident Cases to Evaluate Prognostic Markers with Time-Varying Performance
Aasthaa Bansal, University of Washington; Patrick Heagerty, University of Washington
11:50 AM
|
Identifying Epigenomic Biomarkers for Anticancer Drug Responses by Integrating Gene Expression and DNA Methylation Profiles
Zhibao Mi, VA; Kui Shen, Department of Obstetrics, Gynecology & Reproductive Sciences, University of Pittsburgh; Nan Song, the NSABP Foundation, Inc.
12:15 PM
|
Clinical Trial Designs for Biomarker Research in Oncology
Sumithra Mandrekar, Mayo Clinic
2:05 PM
|
Assessment of Biomarker Prediction Accuracy Under Marker-Dependent Sampling
Xiaofei Wang, Duke University Medical Center; Junling Ma, Shanghai University of Finance and Economics; Stephen George, Duke University Medical Center
2:25 PM
|
Finding the Biologically Optimal Dose with Early Efficacy Biomarkers in Phase I Cancer Clinical Trials
Rui Qin, Mayo Clinic
2:25 PM
|
Locally Smoothed Statistical Learning for Age-Dependent Classification and Disease Risk Prediction
Huaihou Chen, New York University; Tianle Chen, Columbia University; Donglin Zeng, The University of North Carolina; Yuanjia Wang, Columbia University
2:30 PM
|
Latent Class Regression Model for Assessment of Diagnostic Tests in the Absence of a Gold Standard, with Accommodation for Covariate Information
Zheyu Wang, University of Washington; Xiao-Hua Andrew Zhou, University of Washington
2:55 PM
|
Identifying Subpopulations with Differential Risk Benefit Profiles
Tianxi Cai, Harvard University
3:20 PM
|
Longitudinal Analysis of Left-Censored Serum C-Terminal Telopeptide (sCTX) Levels in Treated Women with Postmenopausal Osteoporosis
Matthew Austin, Amgen, Inc.; Angela Tang, Amgen, Inc; Nadia Daizadeh, Amgen, Inc
3:20 PM
|
|
Wednesday, 08/07/2013
|
Calibration Problems with Panel Data Applied to Alzheimer's Disease Biomarkers
Huanli Wang, University of California, Davis; Danielle Harvey, UC Davis; Laurel Beckett, UC Davis
|
How to Maximize the Usefulness of Predictive Biomarker Data in Development of Personalized Medicines
Cong Chen, Merck and Company Inc
8:35 AM
|
Unblinded Adaptive Statistical Information Designs: Clinical Endpoint With or Without Biomarker
Sue-Jane Wang, Food and Drug Administration
9:25 AM
|
Semiparametric Robust Methods for Biomarker Discovery Among Potential Confounders: A Marriage of Targeted Maximum Likelihood Estimation and Limma
Sara Kherad-Pajouh, University of California, Berkeley; Alan Hubbard, UC Berkeley; Cliona M. McHale, University of California at Berkeley; Luoping Zhang , University of California at Berkeley; Martyn T. Smith, University of California at Berkeley
9:50 AM
|
Comparative Effectiveness Research for Diagnostic Tests and Biomarkers
Constantine Gatsonis, Brown University
10:35 AM
|
Bayesian Multiple Biomarker Subgroup Selection
Zhaowei Hua, Millennium: The Takeda Oncology Company; Mingxiu Hu, Millennium: The Takeda Oncology Company; Chuanhua Xing, Boston University
11:35 AM
|
Introduction to Joint Modeling of Longitudinal Biomarkers and Kidney Disease Outcomes
Tom Greene, University of Utah; Ken Boucher, University of Utah
2:05 PM
|
Time-Dependent ROC Analysis for Early Detection of End-Stage Renal Disease (ESRD) Using Baseline Glomerular Filtration Rate
Nan Hu, University of Utah
2:45 PM
|
Threshold-Dependent Proportional Hazards Model for Current Status Data with Biomarker Subject to Measurement Error
Noorie Hyun, The University of North Carolina; Donglin Zeng, The University of North Carolina; David Couper, The University of North Carolina; James Pankow, University of Minnesota
3:20 PM
|
|
Thursday, 08/08/2013
|
Challenges in Evaluation of Correlates of Protection and Immunobridging in Vaccine Trials
Peter Gilbert, University of Washington and Fred Hutchinson Cancer Research Center; Ivan S. F. Chan, Merck Research Laboratories; Ghideon Ghebregiorgis, CBER/FDA; Catherine Njue, Health Canada
8:35 AM
|
Impact of Correlation on Predictive Ability of a Biomarker
Olga Demler, BWH; Michael Pencina, Boston University; Ralph D'Agostino, Sr., Boston University
8:50 AM
|
A Test Based on Monte Carlo Simulations for Biomarker-Adaptive Threshold Design
Yafeng Zhang, UCLA; Glen Laird, Bristol-Myers Squibb
9:20 AM
|
Sequential Testing of the Empirical Positive and Negative Predictive Value Curves with Unknown Prevalence
Joseph S. Koopmeiners, University of Minnesota; Ziding Feng, Fred Hutchinson Cancer Research Center
10:35 AM
|
|
Copyright © American Statistical Association.